¼¼°èÀÇ °£Áúȯ Áø´Ü ½ÃÀå
Liver Disease Diagnostics
»óǰÄÚµå : 1777386
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 380 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °£Áúȯ Áø´Ü ½ÃÀåÀº 2030³â±îÁö 496¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 366¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â °£Áúȯ Áø´Ü ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 5.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 496¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀÓ»ó °Ë»ç´Â CAGR 5.4%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 168¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿µ»ó Áø´Ü ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 3.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 100¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °£Áúȯ Áø´Ü ½ÃÀåÀº 2024³â¿¡ 100¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 99¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.3%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.5%¿Í 5.2%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.4%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ °£Áúȯ Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°£Áúȯ Áø´ÜÀÇ Á߿伺ÀÌ Ä¿Áö´Â ÀÌÀ¯

°£¿°, Áö¹æ°£, °£°æº¯, °£¼¼Æ÷¾Ï(HCC) µî °£ ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ °í±Þ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °£ÁúȯÀº ¾ËÄÚ¿Ã ¼·Ãë, ºñ¸¸, ´ë»ç ÀÌ»ó°ú °°Àº »ýȰ½À°ü ¿äÀο¡ ÀÇÇØ ¾ÇÈ­µÇ¸ç, ¿©ÀüÈ÷ Àü ¼¼°èÀûÀ¸·Î Å« °Ç°­ ºÎ´ãÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ºñ¾ËÄڿüº Áö¹æ°£Áúȯ(NAFLD)°ú ºñ¾ËÄڿüº Áö¹æ°£¿°(NASH)ÀÇ ¹ßº´·ü Áõ°¡·Î ÀÎÇØ Á¶±â¿¡ Á¤È®ÇÑ Áø´ÜÀÇ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù. °£ ±â´É °Ë»ç, ¿µ»ó ±â¼ú, »ý°Ë°ú °°Àº ÀüÅëÀûÀÎ Áø´Ü ¹æ¹ýÀº ÷´Ü ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý ºÐ¼®, ºñħ½ÀÀû ¿µ»ó ¼Ö·ç¼Ç, AI ±â¹Ý Áø´Ü Ç÷§ÆûÀ¸·Î º¸¿ÏµÇ°í ÀÖ½À´Ï´Ù. °¢±¹ Á¤ºÎ¿Í ÀÇ·á ±â°üÀº Áúº´ Á¶±â ¹ß°ßÀÇ Á߿伺À» ÀνÄÇϰí, Àû½Ã¿¡ °³ÀÔÇÏ¿© ÀÌȯÀ²°ú »ç¸Á·üÀ» ³·Ãß±â À§ÇØ Áúº´ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀνÄÀ» Á¦°íÇϰí ÀÚ±ÝÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á·ÎÀÇ ÀüȯÀº °£Áúȯ Áø´ÜÀ» À§ÇÑ Çõ½ÅÀûÀÎ µµ±¸ÀÇ Çʿ伺À» ´õ¿í ºÎÃß±â°í ÀÖÀ¸¸ç, °³Àκ° À§Çè¿äÀΰú Áúº´ ÁøÇà¿¡ µû¸¥ ¸ÂÃãÇü Ä¡·á Á¢±ÙÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

°£Áúȯ Áø´ÜÀ» °­È­ÇÏ´Â ±â¼ú Çõ½ÅÀº ¾î¶² °ÍÀÌ ÀÖÀ»±î?

±â¼úÀÇ ¹ßÀüÀº °£Áúȯ Áø´ÜÀÇ Á¤È®¼º, È¿À²¼º, Á¢±Ù¼ºÀ» Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ ±â¼ú Çõ½Å Áß Çϳª´Â ¿¤¶ó½ºÅä±×·¡ÇÇ¿Í °°Àº ºñħ½ÀÀû Áø´Ü ±â¼úÀÇ °³¹ß·Î, »ý°Ë ¾øÀ̵µ °£ °æµµ¸¦ Æò°¡ÇÏ°í ¼¶À¯È­¸¦ °¨ÁöÇÒ ¼ö ÀÖ´Â ±â¼úÀÔ´Ï´Ù. AI¸¦ žÀçÇÑ ¿µ»ó ¼Ö·ç¼Çµµ ÀÚµ¿È­µÈ ÆÐÅÏ Àνİú ¿¹Ãø ºÐ¼®À» ÅëÇØ °£ ÀÌ»ó ¡Èĸ¦ °¨ÁöÇÏ´Â ±â´ÉÀ» °­È­ÇÔÀ¸·Î½á Áø´Ü¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. Ç÷¾× »ùÇÿ¡¼­ °£ÁúȯÀÇ ¹ÙÀÌ¿À¸¶Ä¿¸¦ °ËÃâÇÒ ¼ö ÀÖ´Â ¾×ü»ý°Ë ±â¼úÀÇ µîÀåµµ ȹ±âÀûÀ̾ ħ½ÀÀû ½Ã¼úÀÇ Çʿ伺ÀÌ ÁÙ¾îµé¾ú½À´Ï´Ù. ¶ÇÇÑ, À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, ´ë»çüÇÐÀ» ÅëÇÕÇÑ ¸ÖƼ¿À¹Í½º Á¢±Ù¹ýÀº °£ÁúȯÀÇ º´Å»ý¸® ¹× ÁøÇà¿¡ ´ëÇÑ ±íÀº ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ¿ø°Ý ÀÇ·á¿Í ¿ø°Ý Áø´Ü ¼Ö·ç¼ÇÀÇ ÅëÇÕÀº °£ Áúȯ °ËÁø¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ´õ¿í È®´ë½Ã۰í ÀÖÀ¸¸ç, ƯÈ÷ ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­ ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¿¬±¸ °³¹ßÀÌ ÁøÇàµÊ¿¡ µû¶ó Â÷¼¼´ë Áø´Ü µµ±¸´Â Àü ¼¼°è °£ Áúȯ ȯÀÚÀÇ Á¶±â ¹ß°ßÀ²°ú Ä¡·á °á°ú¸¦ °³¼±ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀÔ´Ï´Ù.

¼ÒºñÀÚ Æ®·»µå¿Í ÇコÄɾî Á¤Ã¥Àº ¾î¶»°Ô ½ÃÀåÀ» Çü¼ºÇϰí Àִ°¡?

¼ÒºñÀÚ ¼±È£µµÀÇ º¯È­¿Í ÇコÄɾî Á¤Ã¥ÀÇ ÁøÈ­°¡ °£Áúȯ Áø´Ü ½ÃÀåÀÇ ¼ºÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °£ °Ç°­ ¹× ¿¹¹æ °ËÁø¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó, ƯÈ÷ °íÀ§Ç豺ÀÇ °æ¿ì Á¤±âÀûÀÎ Áø´Ü °Ë»ç¸¦ ¹ÞÀ¸·Á´Â »ç¶÷µéÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °¡Á¤¿ë °Ë»ç ŰƮ¿Í µðÁöÅÐ °Ç°­ ¼Ö·ç¼ÇÀÇ µµÀÔÀ¸·Î °£ Áúȯ Áø´ÜÀº ¼ÒºñÀڵ鿡°Ô ´õ¿í Æí¸®ÇÏ°í ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, Á¶±â ¹ß°ßÀ» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í °øÁߺ¸°Ç Ä·ÆäÀÎÀÌ °ËÁø ÇÁ·Î±×·¥¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿Í º¸Çè»çµéµµ °£Áúȯ Á¶±â ¹ß°ßÀÇ ºñ¿ë È¿À²¼ºÀ» ÀνÄÇϰí ÀÖÀ¸¸ç, ÀÌ´Â °í±Þ Áø´Ü °Ë»ç¿¡ ´ëÇÑ º¸Çè Àû¿ë È®´ë¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à»ç¿Í Áø´Ü¾à °³¹ß ±â¾÷°úÀÇ Çù¾÷À¸·Î »õ·Î¿î °£Áúȯ Áø´Ü ±â¼úÀÇ »ó¿ëÈ­°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¸¸¼º °£ ÁúȯÀÇ ºÎ´ãÀ» ÁÙÀÌ´Â °ÍÀÌ Àü ¼¼°èÀûÀ¸·Î °­Á¶µÇ¸é¼­ ±ÔÁ¦ ´ç±¹Àº Çõ½ÅÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀÇ ½ÂÀÎÀ» ½Å¼ÓÇÏ°Ô ÁøÇàÇÏ¿© ½ÃÀå ħÅõ¿Í º¸±ÞÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

°£Áúȯ Áø´Ü ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀº ¹«¾ùÀΰ¡?

°£Áúȯ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº °£Áúȯ À¯º´·ü Áõ°¡, ±â¼ú ¹ßÀü, ÀÇ·á Á¤Ã¥ Áö¿ø µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. BÇü °£¿°, CÇü °£¿°, NAFLD, NASHÀÇ ¹ßº´·ü Áõ°¡·Î ÀÎÇØ Á¶±â¿¡ Á¤È®ÇÑ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿µ»ó Áø´Ü ±â¼ú, ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö, AI ±â¹Ý Áø´Ü Ç÷§ÆûÀÇ Çõ½ÅÀº °£ Áúȯ °ËÃâÀÇ Á¤È®¼º°ú Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀå °Ë»ç ¹× ÈÞ´ë¿ë Áø´Ü±â±âÀÇ ¿ªÇÒ È®´ë·Î Á¶±â Áø´Ü ¹× ȯÀÚ ¸ð´ÏÅ͸µÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ÀÇ·á ¹× AI ÀÇ»ç°áÁ¤ Áö¿ø°ú °°Àº µðÁöÅÐ Çコ ±â¼úÀÇ ÅëÇÕÀº Áø´Ü ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí ȯÀÚ °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ¿¹¹æÀû °Ç°­°ü¸®¿Í Á¤±âÀûÀÎ °£ ±â´É °ËÁø¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå È®´ë°¡ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í »õ·Î¿î Áø´Ü ±â¼ú¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀ¸·Î Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀÇ ¾ÈÁ¤ÀûÀÎ ÆÄÀÌÇÁ¶óÀÎÀÌ È®º¸µÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ Áúº´ÀÇ Á¶±â ¹ß°ß°ú °³ÀÎ ¸ÂÃãÇü ÀǷḦ ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, °£Áúȯ Áø´Ü ½ÃÀåÀº Áö¼ÓÀûÀÎ ¼ºÀå¼¼¸¦ º¸À̸ç ȯÀÚ °ü¸® ¹× Ä¡·á Àü·« °³¼±ÀÇ ±æÀ» ¿­¾îÁÙ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ºÎ¹®

Áø´Ü ±â¼ú(ÀÓ»ó °Ë»ç, ¿µ»ó Áø´Ü, ³»½Ã°æ °Ë»ç, »ý°Ë, ±âŸ);Áúȯ(NAFLD, NASH, ¼¶À¯Áõ, °£°æº¯, HCC, ±âŸ);ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, ¿¬±¸¼Ò, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Liver Disease Diagnostics Market to Reach US$49.6 Billion by 2030

The global market for Liver Disease Diagnostics estimated at US$36.6 Billion in the year 2024, is expected to reach US$49.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$16.8 Billion by the end of the analysis period. Growth in the Imaging segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.0 Billion While China is Forecast to Grow at 8.3% CAGR

The Liver Disease Diagnostics market in the U.S. is estimated at US$10.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.9 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Liver Disease Diagnostics Market - Key Trends & Drivers Summarized

Why Is Liver Disease Diagnostics Gaining Critical Importance?

The increasing prevalence of liver diseases, including hepatitis, fatty liver disease, cirrhosis, and hepatocellular carcinoma (HCC), is driving the demand for advanced diagnostic solutions. Liver disease remains a significant global health burden, exacerbated by lifestyle factors such as alcohol consumption, obesity, and metabolic disorders. The rising incidence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has further intensified the need for early and accurate diagnostics. Traditional diagnostic methods such as liver function tests, imaging techniques, and biopsies are being supplemented by advanced biomarker-based assays, non-invasive imaging solutions, and AI-driven diagnostic platforms. Governments and healthcare organizations are increasing awareness and funding for early disease detection, recognizing the importance of timely intervention in reducing morbidity and mortality rates. Additionally, the shift towards personalized medicine is further fueling the need for innovative liver disease diagnostic tools, enabling tailored treatment approaches based on individual risk factors and disease progression.

What Innovations Are Enhancing Liver Disease Diagnostics?

Technological advancements are significantly improving the accuracy, efficiency, and accessibility of liver disease diagnostics. One of the most notable innovations is the development of non-invasive diagnostic techniques, such as elastography, which assesses liver stiffness and detects fibrosis without the need for a biopsy. AI-powered imaging solutions are also revolutionizing diagnostics by enhancing the detection of liver abnormalities through automated pattern recognition and predictive analytics. The emergence of liquid biopsy technology is another breakthrough, allowing for the detection of liver disease biomarkers in blood samples, reducing the need for invasive procedures. Additionally, multi-omics approaches, integrating genomics, proteomics, and metabolomics, are offering deeper insights into liver disease pathophysiology and progression. The integration of telemedicine and remote diagnostic solutions is further expanding access to liver disease screening, particularly in underserved regions. As research and development continue to advance, next-generation diagnostic tools will play a critical role in improving early detection rates and treatment outcomes for liver disease patients worldwide.

How Are Consumer Trends and Healthcare Policies Shaping the Market?

Shifting consumer preferences and evolving healthcare policies are playing a crucial role in the growth of the liver disease diagnostics market. The rising awareness of liver health and preventive screening is driving more individuals to seek regular diagnostic testing, particularly in high-risk populations. The adoption of at-home testing kits and digital health solutions is making liver disease diagnostics more convenient and accessible to consumers. Additionally, government initiatives and public health campaigns promoting early detection are fostering higher demand for screening programs. Healthcare providers and insurance companies are also recognizing the cost-effectiveness of early liver disease detection, leading to expanded coverage for advanced diagnostic tests. Furthermore, collaborations between pharmaceutical companies and diagnostic developers are accelerating the commercialization of novel liver disease diagnostic technologies. The global emphasis on reducing the burden of chronic liver conditions is driving regulatory agencies to fast-track approvals for innovative diagnostic solutions, ensuring wider market penetration and adoption.

What Are the Key Growth Drivers Fueling the Liver Disease Diagnostics Market?

The growth in the liver disease diagnostics market is driven by several factors, including the increasing prevalence of liver disorders, technological advancements, and supportive healthcare policies. The rising incidence of hepatitis B and C, NAFLD, and NASH is creating a strong demand for early and accurate diagnostic tools. Innovations in imaging techniques, biomarker discovery, and AI-driven diagnostic platforms are improving the precision and accessibility of liver disease detection. The expanding role of point-of-care testing and portable diagnostic devices is also enhancing early diagnosis and patient monitoring. Additionally, the integration of digital health technologies, such as telemedicine and AI-assisted decision support, is streamlining diagnostic workflows and improving patient outcomes. The growing focus on preventive healthcare and routine liver function screening is further bolstering market expansion. Moreover, increasing investments in research and development, coupled with regulatory support for novel diagnostic technologies, are ensuring a steady pipeline of innovative solutions. As global healthcare systems prioritize early disease detection and personalized medicine, the liver disease diagnostics market is expected to witness sustained growth, paving the way for improved patient care and treatment strategies.

SCOPE OF STUDY:

The report analyzes the Liver Disease Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis Technique (Laboratory Tests, Imaging, Endoscopy, Biopsy, Others); Disease (NAFLD, NASH, Fibrosis, Cirrhosis, HCC, Others); End-Use (Hospitals, Laboratories, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â